Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade
Introduction
Pancreatic neuroendocrine tumors (PanNETs) are rare pancreatic neoplasma with an annual incidence of 2.2 per 1,000,000 individuals [1]. However, PanNETs are clinically important, given their high rate of malignancy. Contrast-enhanced computed tomography (CT) is a widely accepted technique for the detection and staging of pancreatic tumors. This technique is usually performed as a multiphase dynamic study, and the pancreatic parenchymal or portal venous phase can facilitate the detection of PanNETs [2], [3]. Many studies have reported the radiologic findings of PanNETs [4], [5], [6]. Typical PanNETs show hyperattenuation during the pancreatic parenchymal and portal venous phases because of their rich blood capillary networks [5].
In 2000, the World Health Organization (WHO) classification for PanNETs identified lesions exhibiting malignant behaviors on the basis of tumor cell differentiation [7]. Subsequently, in 2010, the updated WHO classification divided neuroendocrine tumors into the categories of NETG1, NETG2, and NEC, according to the pathological tumor grade, which is an independent prognostic factor of survival in patients with PanNETs [8], [9], [10]. Therefore, pretreatment prediction of the PanNET pathological tumor grade according to the recent WHO classification is very important in determining an efficient treatment strategy. Studies on the relationship between contrast-enhanced CT findings and prognostic factors, including pathological tumor grades according to the previous WHO PanNET classification, have been reported [11], [12], [13]. However, there is a paucity in research on the relationship between contrast-enhanced CT findings and pathological tumor grades according to the recent WHO PanNET classification [14]. Therefore, the purpose of this study was to determine whether CT features can predict the pathological tumor grades of PanNETs according to the recent WHO classification.
Section snippets
Patients
Institutional ethics review board approval was obtained and informed consent was waived for this retrospective study. We queried our institutions’ pathology databases to identify all histologically proven PanNET cases during a period from September 2004 to November 2011, and identified 30 patients with PanNETs who were considered for inclusion in this retrospective study. All patients underwent preoperative dynamic-enhanced CT examinations to evaluate pancreatic tumors. We excluded 2 patients
Results
The interobserver agreements ranged from moderate to near-perfect (κ = 0.70 for tumor margin delineation, κ = 1.00 for peripancreatic vascular involvement, κ = 0.91 for upstream pancreatic duct dilatation, κ = 0.70 for the N grade, κ = 0.84 for the M grade, κ = 1.00 for tumor homogeneity during the pancreatic parenchymal phase, κ = 0.85 for tumor homogeneity during the portal venous phase, κ = 0.85 for tumor homogeneity during the delayed phase, κ = 0.87 for cystic or necrotic change, κ = 0.92 for tumor
Discussion
In this study, we sought to determine whether the CT features of PanNETs could facilitate the differentiation of G2 from G1. Gallotti et al. [12] classified PanNETs into 2 groups according to the 2000 WHO classification as follows: benign PanNETs, which were defined as a well-differentiated endocrine tumor with benign behavior; and non-benign PanNETs, which included well-differentiated endocrine tumors with uncertain behavior, well-differentiated endocrine carcinomas, and poorly differentiated
Conflicts of interest
None of the authors have any conflicts of interest associated with this study.
References (27)
- et al.
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
Ann Oncol
(2008) - et al.
Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival
Pancreatology
(2006) - et al.
CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification
Eur J Radiol
(2007) - et al.
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor
Surgery
(2011) - et al.
Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors
Gastroenterology
(2003) - et al.
Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection
Radiology
(2000) - et al.
Preoperative detection of pancreatic insulinomas on multiphasic helical CT
Am J Roentgenol
(2003) - et al.
Multi-detector row CT of pancreatic islet cell tumors
Radiographics
(2006) - et al.
Pancreatic endocrine tumors: radiologic-clinicopathologic correlation
Radiographics
(2010) - et al.
Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT
Am J Roentgenol
(2013)
World Health Organization international histological classification of tumours: histological typing of endocrine tumours
Neuroendocrine neoplasms of the pancreas
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors
Cancer
Cited by (81)
Preoperative assessment of microvessel density in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs)
2022, Surgery (United States)Prognostic value of CT characteristics in GEP-NET: A systematic review
2022, Critical Reviews in Oncology/HematologyThe diagnostic value of intravoxel incoherent motion diffusion-weighted imaging for distinguishing nonhypervascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas
2022, European Journal of RadiologyCitation Excerpt :However, ADC values of nonhypervascular PNETs were significantly lower than PDACs in our study. The enhancement pattern of PNET was related with tumor grade [24], and nonhypervascular PNETs were more commonly high-grade tumors (G2/G3 grades) in our study, as previously reported in the literature [14,15]. As tumor grade increases, the increase of cell density and nuclear-to-cytoplasmic ratios lead to the restricted diffusion of water molecules [25], resulting in a lower ADC value in the nonhypervascular PNETs.
Enhanced computed tomography features predict pancreatic neuroendocrine neoplasm with Ki-67 index less than 5%
2022, European Journal of RadiologyNon-gaussian models of 3-Tesla diffusion-weighted MRI for the differentiation of pancreatic ductal adenocarcinomas from neuroendocrine tumors and solid pseudopapillary neoplasms
2021, Magnetic Resonance ImagingCitation Excerpt :According to recent reports, up to 42%–49% of PNETs may not present arterial enhancement, and these non-hypervascular PNETs may be difficult to distinguish from PDACs [10,11]. So, the differential diagnosis of solid pancreatic tumors based on both clinical and imaging manifestation is a challenge when the findings are atypical [15]. Therefore, new abdominal imaging techniques are needed to improve the diagnostic performance of differentiating PDACs from SPNs and PNETs.
Contrast-Enhanced Ultrasonography Findings Correlate with Pathologic Grades of Pancreatic Neuroendocrine Tumors
2021, Ultrasound in Medicine and Biology